{
    "nct_id": "NCT05565378",
    "official_title": "A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer",
    "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or non squamous)\n* No prior systemic therapy for their locally advanced or metastatic NSCLC\n* Provides a fresh tumor tissue sample or archival sample collected within 2 years prior to screening\n* PD-L1-high (TC/TPS >= 50%) tumor\n* Measurable disease based on RECIST 1.1, as determined by the investigator\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n* Adequate Baseline organ function\n* Female participants of childbearing potential must use adequate contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Presence of Epidermal growth factor receptor (EGFR) mutations, Anaplastic lymphoma kinase (ALK) translocations, or other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available.\n* Has NSCLC with a tumor that harbors any of the following molecular alterations: EGFR and /or ALK translocations mutations that are sensitive to available targeted inhibitor therapy, Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for first-line treatment of locally advanced or metastatic NSCLC.\n* Had major surgery within 4 weeks or lung radiation of >30 Gy therapy within 6 months prior to the first dose of study intervention\n* Received prior therapy with any immune checkpoint inhibitors\n* Never smoked, defined as smoking <100 tobacco cigarettes in a lifetime\n* Has an invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years (clinical exceptions apply as per protocol)\n* Symptomatic, untreated, or actively progressing, brain metastases or any leptomeningeal disease (regardless of symptomatology, treatment status, or stability)\n* Autoimmune disease or syndrome that required systemic treatment within the past 2 years\n* Receiving systemic steroid therapy <= 3 days prior to first dose of study intervention or any form of immunosuppressive medication\n* Received any live vaccine <= 30 days prior to first dose of study intervention\n* Any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis\n* History or evidence of cardiac abnormalities\n* Current unstable liver or biliary disease\n* Severe infection within 4 weeks prior to the first dose of study intervention\n* Positive for tuberculosis, human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or hepatitis C\n* Has advanced, symptomatic, or visceral spread and is considered to be at imminent risk of life-threatening complications (including, but not limited to, massive uncontrolled effusions [e.g., pleural, pericardial, peritoneal])\n* Is currently participating in or has participated in a study of an investigational therapy within 4 weeks prior to the first dose of study intervention\n* Has a history of allogeneic tissue/stem cell transplant or solid organ transplant",
    "miscellaneous_criteria": ""
}